Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II trial of elderly patients (> 70 years of age). Patients in this age
group with previously un-treated Advanced Stage Non-Squamous Non-Small Cell Lung Cancer
(NSCLC) with Stage IIIB (with malignant pleural effusion) and stage IV disease will be
enrolled. Therapy consists of three drugs (Premetrexed[Alimta™], Bevacizumab and
Erlotinib[Tarceva™]) which are given every 28 days.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute